Popular terms

Immune Diseases topics
Immune Diseases
Autoimmune
Immune Disease
Autoimmune Disease
Autoimmune Diseases
Immune Disorder
Rheumatoid Arthritis
Antibodies
Antagonist
Nucleotide
Proliferative
Infectious
Infectious Disease
Infectious Diseases
Type 1 Diabetes

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immune Diseases patents



      

This page is updated frequently with new Immune Diseases-related patent applications.




Date/App# patent app List of recent Immune Diseases-related patents
04/07/16
20160095895 
Highly concentrated formulations of soluble fc receptors
The present invention relates to novel formulations of soluble fc receptors and especially to formulations containing high concentrations of soluble fcγriib receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved..
Suppremol Gmbh


04/07/16
20160095839 
Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions
Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases.. .
Caliper Life Sciences, Inc.


03/24/16
20160083473 
Bispecific constructs and their use in the treatment of various diseases
The present invention relates to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to il23r-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in treating inflammatory and/or autoimmune diseases and/or cancer.. .
Numab Ag


03/24/16
20160082017 
Estriol therapy for multiple sclerosis and other autoimmune diseases
The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (ms), rheumatoid arthritis (ra), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis..

03/17/16
20160075999 
Method for enhancing therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases
A method for enhancing the therapeutic effect of a stem cell on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell.
Gwo Xi Stem Cell Applied Technology Co., Ltd.


03/17/16
20160075790 
Antibody polypeptides that antagonize cd40l
Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Bristol-myers Squibb Company


03/17/16
20160075739 
Peptide for inducing mast cell-specific apoptosis and use thereof
A peptide according to the present invention can perform a function identical or similar to the function of natural ctla-4 and has an excellent degree of skin penetration due to a small size. The peptide according to the present invention effectively binds to antigen presenting cell surface proteins (cd80 and cd86) to inhibit activity of t cells and thus is capable of inhibiting the expression of inflammatory cytokines (for example, il-2 and ifn-γ).
Caregen Co., Ltd.


03/17/16
20160074505 
Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
A method and system for targeting the microbiome to promote health involves exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies and autoimmune diseases. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments..

03/17/16
20160074394 
Method of treatment
The present invention relates to a method of treating t cell mediated inflammatory immune diseases or t cell mediated hypersensitivity diseases, which comprises administering to a human in need thereof an effective amount of a compound which inhibits ezh2 and/or ezh1, or a pharmaceutically acceptable salt thereof.. .
Glaxosmithkline Intellectual Property (no. 2) Limited


03/10/16
20160069896 
Diagnosis of autoimmune diseases using a specific antibody profile
Methods and kits for diagnosing systemic lupus erythematosus (sle) or scleroderma in a subject are provided. Particularly, the present invention relates to a specific antibody reactivity profile useful in diagnosing sle or scleroderma in a subject..
Yeda Research And Development Co., Ltd.


03/10/16
20160068809 

Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants


The invention relates to the use of 1-(β-d-ribofuranosyl)-1,2-dihydropyrimidin-2-one derivative or mimetic or an analogue, derivatives, metabolites, variants or salts thereof for the manufacturing of a medicament to increase the amount of indoleamine 2,3-dioxygenase (ido) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.. .
Idogen Ab


03/10/16
20160068534 

Inhibitors of leukotriene a4 hydrolase


The present invention is directed to compounds encompassed by the formula (i), pharmaceutical compositions thereof, methods for inhibiting lta-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of lta4h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders..
Celtaxsys, Inc.


03/10/16
20160068524 

Inhibitors of leukotriene a4 hydrolase


The present invention is directed to compounds encompassed by the formula (i), pharmaceutical compositions thereof, methods for inhibiting lta-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of lta4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders..
Celtaxsys, Inc.


03/10/16
20160068522 

Inhibitors of leukotriene a4 hydrolase


The present invention is directed to compounds encompassed by the formula (i), pharmaceutical compositions thereof, methods for inhibiting lta-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of lta4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders..
Celtaxsys, Inc.


03/10/16
20160067272 

Methods for treating immune diseases


Provided herein are methods for treating or preventing an immune disease in a subject by administering a composition comprising a therapeutically effective amount of nad+. Also provided herein are methods and assays for diagnosing an immune disease in a subject by measuring the level of nad+ in a biological sample obtained from the subject..
The Brigham And Women's Hospital, Inc.


03/03/16
20160060700 

Copy number variations and autoimmune diseases


This disclosure describes methods of determining the copy number of fcgr3a and/or fcgr3b in the genome of an individual, which is shown herein to be statistically significantly associated with an increased risk of the individual developing an autoimmune disease.. .
Regents Of The University Of Minnesota


03/03/16
20160060351 

Use of c5ar antagonists


C5a and c5ar stimulate the inflammatory response and c5ar antagonist can counteract this function performing as an anti-inflammatory agents. This functionality is considered useful in treatment of inflammatory diseases including auto immune diseases.
Novo Nordisk A/s


03/03/16
20160060348 

Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and use in therapy


Improved anti-cd154 antibodies are provided herein which have ablated fcr binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein..
The Trustees Of Dartmouth College


03/03/16
20160060299 

Macrocyclic therapeutic agents and methods of treatment


The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.. .
University Of Florida Research Foundation, Inc.


03/03/16
20160060264 

Urea derivatives and uses thereof


The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.


03/03/16
20160060237 

Ido inhibitors


There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (ido), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. Formula (i)..
Bristol-myers Squibb Company


03/03/16
20160058792 

Methods and compositions of treating autoimmune diseases


Embodiments of various aspects described herein are directed to methods and compositions for producing a tolerogenic or immunosuppressive dendritic cell. In particular, an immunosuppressive dendritic cell can be produced by contacting a dendritic cell with an agent that stimulates the il 27/ectonucleotidase cd39 axis signaling.
The Brigham And Women's Hospital, Inc.


02/25/16
20160053007 

Antibodies that bind to tl1a and methods of treating inflammatory or autoimmune disease comprising administering such antibodies


Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between dr3 and tl1a. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a t cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease..
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services


02/25/16
20160052888 

Substituted bicyclic compounds


And/or a salt thereof, wherein r1 is —oh or —op(o)(oh)2, and x1, x2, x3, r2, r2a, ra, rb, and rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.

02/25/16
20160052876 

Cryopyrin inhibitors for preventing and treating inflammation


Inhibitors that are anti-inflammatory agents are provided, as are methods of using the analogs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as heart failure and autoimmune diseases.. .
Virginia Commonwealth University


02/25/16
20160051671 

Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease


The invention relates to novel combination therapies involving blys or blys/april inhibition and anti-cd20 agents for the treatment of autoimmune diseases. One preferred method is where the blys antagonist is a fc-fusion protein which can be a taci-fc-fusion protein comprising the extracellular domain of taci or a functional fragment thereof, a baff-r-fc-fusion protein comprising the extracellular domain of baff-r or a functional fragment thereof, or a bcma-fc-fusion protein comprising the extracellular domain of bcma or a functional fragment thereof.
Zymogenetics, Inc.


02/25/16
20160051573 

Structure and use of 5' phosphate oligonucleotides


Oligonucleotides bearing free, uncapped 5′ phosphate group(s) are recognized by rig-i, leading to the induction of type i ifn, il-18 and il-1β production. Bacterial rna also induces type i ifn production.
Rheinische Friedrich-wilhelms-universität Bonn


02/18/16
20160046714 

Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity


The present invention provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of t cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes (i.e. Type 1 diabetes or insulin-dependent diabetes mellitus (iddm)) and multiple sclerosis) through the use of anti-human cd3 antibodies.
Macrogenics, Inc.


02/18/16
20160046661 

Ras inhibitors and uses thereof


Described herein are compounds of formulae (i)-(ii), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject..
Dana-farber Cancer Institute, Inc.


02/18/16
20160046619 

Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities


Which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-fms (csf-1r), c-kit, and/or pdgfr kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-fms, c-kit, or pdgfr kinases..

02/18/16
20160046602 

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..

02/18/16
20160045503 

Formulations containing reversible covalent compounds


Oral pharmaceutical formulations comprising reversible covalent compounds having a michael acceptor moiety, a process of their production and use of these formulations for the treatment of diseases treatable by such compounds such as cancer and autoimmune diseases.. .
Principia Biopharma Inc.


02/11/16
20160039905 

B7-h4 fusion proteins and methods of use thereof


Fusion proteins containing b7-ii4 polypeptides are disclosed. The b7-h4 fusion proteins can include full-length b7-h4 polypeptides, or can contain a fragment of a full-length b7-h4 polypeptide, including some or all of the extracellular domain of the b7-h4 polypeptide.
Amplimmune, Inc.


02/11/16
20160039807 

Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)


Wherein cy, l1, g, and r1 are as described herein. The present invention relates to novel compounds according to formula (i) that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis), lung diseases (e.g.

02/11/16
20160039784 

Pyrazole derivative


Provided are a compound expressed by formula (i) or a pharmacologically permissible salt thereof, as well as a drug or drug composition that contains this compound as an active ingredient, having a xanthine oxidase inhibiting effect that is very useful for treating or preventing diseases that are contributed to by xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stones, hypertension, dyslipidemia, diabetes, cardiovascular disease such as heart failure and arterial sclerosis, renal disease such as diabetic near opacity and the like, respiratory disease such as chronic obstructive pulmonary disease and the like, autoimmune diseases such as inflammatory bowel disease, and the like. [in the formula, a, x, y, z, r, and r1 have the meaning set forth in claim 1]..
Teijin Pharma Limited


02/11/16
20160038496 

Novel formulations of a bruton's tyrosine kinase inhibitor


Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc


02/04/16
20160033528 

Methods for selecting peptides that bind to disease specific antibodies, disease specific peptides and uses thereof


Provided herein is a method for selecting and expanding polypeptide epitopes against disease-specific antibodies present in blood across a wide variety of antibody-mediated infectious and autoimmune diseases. In particular, high-throughput selection methods are provided for selecting and expanding disease-relevant polypeptide epitopes against disease-specific antibodies present in a sample from a subject using polypeptide epitope libraries.
The Regents Of The University Of California


02/04/16
20160032018 

Use of igg1 immunoglobulins and/or ligands of the cd32 receptor for treating inflammatory diseases and incidents via the mucosa


The present invention concerns the use of immunoglobulins of igg1 type, and more generally of ligands of the cd32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.. .
Stallergenes Sa


02/04/16
20160031934 

Dipeptide and tripeptide epoxy ketone protease inhibitors


Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of formula (x): and pharmaceutically acceptable salts and compositions including the same.
Onyx Therapeutics, Inc.


02/04/16
20160031891 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are amido compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.

02/04/16
20160030439 

Methods for the treatment of autoimmune diseases


The present invention provides a method for inducing cd8+foxp3+ regulatory t cells in a subject which comprises administering to the subject: (i) a first agent which inhibits p38 phosphorylation; and (ii) a second agent which stimulates t-cell receptor (tcr) signalling. The method may be used to treat and/or prevent an autoimmune and/or inflammatory disease in a subject.
Ucl Business Plc


01/28/16
20160024508 

Method for identifying biologically active oligonucleotides capable of modulating the immune system


The present invention relates to methods of identifying oligonucleotides capable of modulating the immune system in a mammalian subject, comprising analysis of which tertiary structural type said oligonucleotide adopts, in phosphate-buffered saline solution. Further, the invention provides oligonucleotides identifiable by the methods of the invention and to their use in methods of treating diseases, such as inflammatory diseases, autoimmune diseases, infectious diseases, neurodegenerative diseases and cancer..
Index Pharmaceuticals Ab


01/28/16
20160024220 

Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis


The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-cd6 monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular


01/28/16
20160024219 

Anti-cd52 antibodies


Anti-human cd52 antibodies and antigen-binding fragments thereof are provided. Also provided are isolated nucleic acids, recombinant vectors and host cells for making the antibodies and fragments.
Genzyme Corporation


01/28/16
20160024215 

Llt-1 antibodies with new functional properties


The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (llt1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which llt1- and cd161-expressing cells play a role in disease pathogenesis..
Centre National De La Recherche Scientifique


01/28/16
20160024183 

Synthetic peptides for the treatment of autoimmune diseases


The present invention provides synthetic peptides, including peptides comprising a plurality of epitopes, each epitope being derived from a different protein, and peptides comprising a plurality of citrullinated residues. The present invention also related to use of said peptides for the treatment of autoimmune diseases and disorder..
Tel Hashomer Medical Research Infrastructure And Services Ltd.


01/28/16
20160022788 

Compositions and methods for treating autoimmune diseases


The present invention provides compositions comprising immunologically effective amounts of one or more autoimmune disease associated antigens or antigenic fragments or derivatives thereof and one or more th2 promoting adjuvants. The compositions may optionally comprise one or more th2 promoting tlr2 ligands.
Albany Medical College


01/28/16
20160022767 

Protein particles comprising disulfide crosslinkers and uses


This disclosure relates to particles comprising recombinant proteins, pharmaceutical composition comprising the particles, and therapeutic uses related thereto. In certain embodiments, the particles are made by the process of producing recombinant proteins and conjugating the recombinant proteins to form nanoparticles with a linking reagent comprising disulfide bonds.
Emory University


01/28/16
20160022759 

Methods for increasing the selective efficacy of gene therapy using car peptide and heparan-sulfate mediated macropinocytosis


Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, pah, inflammation, diabetes, crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome.
Vascular Biosciences


01/21/16
20160017024 

Fam150a, fam150b, and fam150 antagonists and uses thereof


Methods of identifying and using fam150a agents, fam150b agents, and fam150 antagonists are provided. Methods of identifying and using ltk agonists (including ltk agonist antibodies, fam150a agents, and fam150b agents) and fam150 antagonists are provided.
Five Prime Therapeutics, Inc.


01/21/16
20160016946 

Methods, compounds, and compositions for the treatment of angiotensin-related diseases


Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer.. .
University Of Southern California


01/21/16
20160016904 

Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof


The present invention relates to processes and intermediates useful in the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of formula (i) and salts thereof, an s1p1 receptor modulator that is useful in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).. .
Arena Pharmaceuticals, Inc.


01/21/16
20160015751 

Method for enhancing a function of a t cell


Disclosed is a method for enhancing the function of a t cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (pd-l1) and/or programmed death-1 ligand 2 (pd-l2) in the t cell. Also disclosed is a function-enhanced t cell which is produced by the function enhancement method.
Takara Bio Inc.


01/21/16
20160015729 

Glycan-based drugs, therapies and biomarkers


The present disclosure discloses simple and efficient glycan- or carbohydrate-based processes or methods for the rapid identification of biological markers and therapeutic targets especially glycan-related targets of infectious diseases, cancers, autoimmune diseases, allergies, inflammation, toxicity, obesity and/or other disorders of humans, animals, plants and other organisms. Therefore, novel methods and products for the diagnosis, prevention, and treatment of such diseases obtainable based on these therapeutic targets can be developed..



Immune Diseases topics: Immune Diseases, Autoimmune, Immune Disease, Autoimmune Disease, Autoimmune Diseases, Immune Disorder, Rheumatoid Arthritis, Antibodies, Antagonist, Nucleotide, Proliferative, Infectious, Infectious Disease, Infectious Diseases, Type 1 Diabetes

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.5494

5394

1 - 1 - 102